Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome

Academic Article
Publication Date:
2016
abstract:
Allogeneic stem cell transplantation (alloHSCT) in first complete remission (CR1) remains the consolidation therapy of choice in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The prognostic value of measurable levels of minimal residual disease (MRD) at time of conditioning is a matter of debate. We analyzed the predictive relevance of MRD levels before transplantation on the clinical outcome of Ph+ ALL patients treated with chemotherapy and imatinib in 2 consecutive prospective clinical trials. MRD evaluation before transplantation was available for 65 of the 73 patients who underwent an alloHSCT in CR1. A complete or major molecular response at time of conditioning was achieved in 24 patients (37%), whereas 41 (63%) remained carriers of any other positive MRD level in the bone marrow. MRD negativity at time of conditioning was associated with a significant benefit in terms of risk of relapse at 5 years, with a relapse incidence of 8% compared with 39% for patients with MRD positivity (P = .007). However, thanks to the post-transplantation use of tyrosine kinase inhibitors (TKIs), disease-free survival was 58% versus 41% (P = .17) and overall survival was 58% versus 49% (P = .55) in MRD-negative compared with MRD-positive patients, respectively. The cumulative incidence of nonrelapse mortality was similar in the 2 groups. Achieving a complete molecular remission before transplantation reduces the risk of leukemia relapse even though TKIs may still rescue some patients relapsing after transplantation.
Iris type:
1.1 Articolo in rivista
Keywords:
Acute lymphoblastic leukemia; Allogeneic transplantation; Minimal residual disease (MRD); Hematology; Transplantation
List of contributors:
Lussana, Federico; Intermesoli, Tamara; Gianni, Francesca; Boschini, Cristina; Masciulli, Arianna; Spinelli, Orietta; Oldani, Elena; Tosi, Manuela; Grassi, Anna; Parolini, Margherita; Audisio, Ernesta; Cattaneo, Chiara; Raimondi, Roberto; Angelucci, Emanuele; Cavattoni, Irene Maria; Scattolin, Anna Maria; Cortelezzi, Agostino; Mannelli, Francesco; Ciceri, Fabio; Mattei, Daniele; Borlenghi, Erika; Terruzzi, Elisabetta; Romani, Claudio; Bassan, Renato; Rambaldi, Alessandro
Authors of the University:
CICERI FABIO
Handle:
https://iris.unisr.it/handle/20.500.11768/58152
Published in:
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Journal
  • Overview

Overview

URL

http://www.bbmt.org/issues
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.11.1.0